Abstract
The aim of this study was to reduce the rate of graft failure after HLA non-identical stem cell transplantation by using G-CSF mobilized CD34+ peripheral blood progenitor cells (PBPC), either in combination with bone marrow or as single grafts. To prevent GVHD, PBPC were highly purified, resulting in a 5 to 6 log T cell depletion. In additon to T cell depletion no further GVHD prophylaxis was used. We transplanted 23 pediatric patients with life-threatening malignant or non-malignant hematological disorders, who had no available matched donor. Engraftment was obtained in 18 of 21 evaluable patients. Five patients developed acute GVHD of grade II and III, which became chronic in four cases and was fatal in four. The use of highly purified PBPC allowed the exact quantification of residual T cells in the grafts and a strict correlation between the residual T cell load and the development of GVHD was observed: patients with GVHD had received numbers of T cells between 8 and 20 × 104/kg, whereas patients without GVHD were grafted with T cell numbers ranging from 0.7 to 6.0 × 104/kg. We therefore clearly demonstrate that a residual T cell content of <5 × 104/kg is safe for prevention of GVHD after HLA non-identical PBPC transplantation in children.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, S., Schulz, A., Reiss, U. et al. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant 24, 575–581 (1999). https://doi.org/10.1038/sj.bmt.1701970
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701970
Keywords
This article is cited by
-
NK cells for cancer immunotherapy
Nature Reviews Drug Discovery (2020)
-
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Cancer Communications (2019)
-
Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT
Bone Marrow Transplantation (2014)
-
Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors
Bone Marrow Transplantation (2009)
-
Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States
Bone Marrow Transplantation (2008)